According to the company, a subretinal injection of ATSN-201 was well tolerated in all patients in the first cohort with extensive resolution of schisis observed in 2 patients. Safety data from the first cohort of the LIGHTHOUSE study will be presented at the Retinal Cell and Gene Therapy Innovation Summit 2024 being held May 3, 2024, in Seattle.
Read More
Study: Pediatric eye care deserts are a growing issue
April 27th 2024Researchers examined disparities in service coverage of pediatric ophthalmologists and pediatric optometrists in relation to patient demographics to cast a light on at-risk populations and provide data for future decisions.
Read More
Ocular Therapeutix announces positive topline Phase 1 data for Axpaxli in diabetic retinopathy
April 19th 2024According to the company, 46.2% of patients demonstrated a 1- or 2-step improvement in the Diabetic Retinopathy Severity Scale (DRSS) at 40 weeks in the Axpaxli arm, compared to 0% in the control arm.
Read More
Oculogenex founder talks about collaboration with NASA and ISS on experiment in macular degeneration
April 11th 2024Hema Ramkumar, an ophthalmologist and founder of Oculogenex, sat down with David Hutton of Ophthalmology Times to discuss their connection with NASA and their experiment on macular degeneration-treated mice in space.
Read More
Orbis, FundamentalVR unveil VR solution that may democratize ophthalmic surgical training
April 6th 2024According to the companies, the tool is affordable, portable, scalable, and intentionally designed to train surgeons in low- and middle-income countries, home to 9 out of 10 people with vision loss due to the difficulty of accessing eye care. The VR tool is being unveiled at the American Society of Cataract and Refractive Surgery Annual Meeting in Boston.
Read More